|
Video: What is a Stock Split?
|
|
Vascular Biogenics is a clinical stage biopharmaceutical company committed to developing targeted medicines for difficult-to-treat medical conditions. Using its platform technologies, Co. has created a pipeline of therapeutics to address cancer and immune-inflammatory diseases. Co.'s product candidates are built off of its two platform technologies: Vascular Targeting System, a gene-based technology targeting newly formed blood vessels, and Monocyte Targeting Technology, an antibody-based technology able to inhibit monocyte migration for immune-inflammatory applications. Co. is evaluating its primary candidate, ofra-vec, in a registration-enabling trial in platinum resistant ovarian cancer. According to our VBLT stock split history records, VBLT has had 0 splits. | |
|
VBLT (VBLT) has 0 splits in our VBLT stock split history database.
Looking at the VBLT stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into VBLT shares, starting with a $10,000 purchase of VBLT, presented on a split-history-adjusted basis factoring in the complete VBLT stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
10/02/2014 |
|
End date: |
10/16/2023 |
|
Start price/share: |
$5.85 |
|
End price/share: |
$0.16 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-97.33% |
|
Average Annual Total Return: |
-33.02% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$266.61 |
|
Years: |
9.04 |
|
|
|
|
|